Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation (ADDF)
Summary
MONTREAL, Jan. 24, 2022 /PRNewswire/ - Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up to US$2.1M investment from the Alzheimers Drug Discovery Foundation (ADDF). The primary focus of the investment from the ADDFs Diagnostics Accelerator is to support the pivotal study for Optinas awAIr TM cerebral amyloid status test when AD is suspected. It is now broadly acknowledged that one key step to improving brain health in the overall medical field lies in a readily accessible, non-invasive, precise, and objective diagnostic test for patients suffering from and/or at risk of cognitive decline. Alzheimers detection, and targeted differentiation from other illnesses associated with memory loss, is one part of Optinas broader brain health platform unlocking the secrets of multiple systemic diseases. A simple eye scan, such as the technology developed by Optina, has the potential to help with early, non-invasive detection of Alzheimers, which is essential to getting the right patients into trials and moving research forward," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF.